VIA
KNSA icon

Virtus Investment Advisers’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Virtus Investment Advisers’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Buy
22,411
+2,111
+10% +$110K 0.33% 130
2026
Q1 		$977K Buy
20,300
+3,868
+24% +$171K 0.27% 142
2025
Q4 		$678K Buy
16,432
+406
+3% +$16.3K 0.18% 187
2025
Q3 		$622K Hold
16,026
– – 0.18% 184
2025
Q2 		$443K Sell
16,026
-1,802
-10% -$45.9K 0.15% 202
2025
Q1 		$396K Buy
+17,828
New +$367K 0.11% 210

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Virtus Investment Advisers's KNSA Position: Q2 2026 in Review

Virtus Investment Advisers increased its Kiniksa Pharmaceuticals (KNSA) stake by 10% in Q2 2026, buying an estimated $110K and bringing the position to 22,411 shares worth $1.43M. The position accounts for 0.33% of the portfolio, ranked #130.

Virtus Investment Advisers first reported a position in KNSA in Q1 2025 and has held it in 6 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Virtus Investment Advisers held 22,411 shares of Kiniksa Pharmaceuticals worth $1.43M as of Q2 2026.
  • Virtus Investment Advisers bought 2,111 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $110K.
  • Kiniksa Pharmaceuticals made up 0.33% of Virtus Investment Advisers's portfolio in Q2 2026, its #130 holding.
  • Virtus Investment Advisers first reported a position in Kiniksa Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.